Mahesh B. Palkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahesh B. Palkar has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Utkarsh U. Bhamare
Department of Pharmaceutical Chemistry, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management SVKM's NMIMS University Mumbai Maharashtra India
6 shared publications- Rajshekhar Karpoormath
Department of Pharmaceutical Chemistry, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
3 shared publications Ab Majeed Ganai
2 shared publications- Chandrakant Bonde
SSR College of Pharmacy, Silvassa 396230, India
2 shared publications - Chitaranjan Mahapatra
University of Bordeaux, France
2 shared publications - Jineetkumar Gawad
VIVA Institute of Pharmacy, Virar (East) 401305, India
2 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9) , e71709
Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure–Activity Relationship Frameworks, Landscapes, and Optimization Approaches
The Akt pathway is dysregulated in cancer, leading to proliferation, decreased apoptosis, and metastasis, and hence is a major therapeutic target in cancer treatment. Over the past two decades, substantial advances have been made in the design of potent, selective, and pharmacokinetically optimized Akt inhibitors. This review analyzes recent Akt inhibitors, with particular focus on the structure–activity relationship (SAR) of their heterocyclic core scaffolds and the resulting biological activity. Additional strategies identified in this review that have yielded promising preclinical and clinical candidates include scaffold optimization, conformational restriction, and hybrid design. Special emphasis is given to advanced inhibitors such as capivasertib, ipatasertib, and NTQ1062, which illustrate the influence of pharmacophoric refinement on therapeutic success. In this review, we integrate knowledge of medicinal chemistry and structure to direct the rational design of next generation Akt inhibitors that are safer and more effective for targeted cancer therapy.
- 27 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9) , e71709
Open AccessDeciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure–Activity Relationship Frameworks, Landscapes, and Optimization Approaches
The Akt pathway is dysregulated in cancer, leading to proliferation, decreased apoptosis, and metastasis, and hence is a major therapeutic target in cancer treatment. Over the past two decades, substantial advances have been made in the design of potent, selective, and pharmacokinetically optimized Akt inhibitors. This review analyzes recent Akt inhibitors, with particular focus on the structure–activity relationship (SAR) of their heterocyclic core scaffolds and the resulting biological activity. Additional strategies identified in this review that have yielded promising preclinical and clinical candidates include scaffold optimization, conformational restriction, and hybrid design. Special emphasis is given to advanced inhibitors such as capivasertib, ipatasertib, and NTQ1062, which illustrate the influence of pharmacophoric refinement on therapeutic success. In this review, we integrate knowledge of medicinal chemistry and structure to direct the rational design of next generation Akt inhibitors that are safer and more effective for targeted cancer therapy.
- 18 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (6) , e71609
From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet
The ketogenic diet (KD), a high‐fat, low‐carbohydrate intervention, is well established for drug‐resistant epilepsy and is increasingly explored in neurodegenerative disorders. KD reduces neuronal hyperexcitability through enhanced γ‐aminobutyric acid (GABA)ergic transmission and modulation of neurotransmitter balance, underlying its efficacy in refractory epilepsy. Beyond seizure control, emerging evidence suggests KD may influence disease processes in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington's disease. Preclinical studies indicate that KD can modulate mitochondrial bioenergetics, oxidative stress, neuroinflammation, neurotransmitter signaling, and gut‐brain interactions, though these effects are highly context‐dependent and primarily derived from cellular and animal models. Clinical data remain limited, heterogeneous, and short‐term, with small cohorts and variable outcome measures. Sustaining adherence and assessing long‐term safety remain significant challenges in patient populations. This review summarizes recent experimental and clinical findings, highlighting the molecular and cellular mechanisms through which KD exerts neuroprotective effects. We also evaluate translational evidence and discuss the potential utility of KD as an adjunctive intervention in neurological disease management.
- 18 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (6) , e71609
From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet
The ketogenic diet (KD), a high‐fat, low‐carbohydrate intervention, is well established for drug‐resistant epilepsy and is increasingly explored in neurodegenerative disorders. KD reduces neuronal hyperexcitability through enhanced γ‐aminobutyric acid (GABA)ergic transmission and modulation of neurotransmitter balance, underlying its efficacy in refractory epilepsy. Beyond seizure control, emerging evidence suggests KD may influence disease processes in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington's disease. Preclinical studies indicate that KD can modulate mitochondrial bioenergetics, oxidative stress, neuroinflammation, neurotransmitter signaling, and gut‐brain interactions, though these effects are highly context‐dependent and primarily derived from cellular and animal models. Clinical data remain limited, heterogeneous, and short‐term, with small cohorts and variable outcome measures. Sustaining adherence and assessing long‐term safety remain significant challenges in patient populations. This review summarizes recent experimental and clinical findings, highlighting the molecular and cellular mechanisms through which KD exerts neuroprotective effects. We also evaluate translational evidence and discuss the potential utility of KD as an adjunctive intervention in neurological disease management.
- 29 November 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (11) , e70343
Expanding Therapeutic Horizons in Parkinson's Disease Through MicroRNA‐Based Interventions: A Comprehensive Review
Parkinson's disease (PD) is a neurodegenerative disorder with rapidly increasing prevalence, characterized by dopaminergic neuronal loss and α‐synuclein aggregation. Current therapies provide only symptomatic benefit and do not alter the disease course. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, are increasingly recognized as key modulators of PD pathogenesis, influencing oxidative stress, mitochondrial dysfunction, neuroinflammation, and proteostasis. Therapeutic modulation of miRNAs in PD has centered on two complementary approaches: miRNA inhibitors (antagomiRs), which silence pathogenic miRNAs, and miRNA mimics (agomiRs), which restore the activity of protective ones. This review integrates current insights into miRNA dysregulation in PD and evaluates the hurdles limiting therapeutic translation. Specific miRNAs such as miR‐7, miR‐153, and miR‐34b/c directly regulate SNCA expression, whereas others influence clearance pathways and stress responses. Although miRNA‐based therapeutics offer considerable promise, their clinical utility remains constrained by challenges of delivery, specificity, and standardization. This review highlights strategies to harness miRNA modulation as a targeted therapeutic avenue in PD.
- 29 November 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (11) , e70343
Expanding Therapeutic Horizons in Parkinson's Disease Through MicroRNA‐Based Interventions: A Comprehensive Review
Parkinson's disease (PD) is a neurodegenerative disorder with rapidly increasing prevalence, characterized by dopaminergic neuronal loss and α‐synuclein aggregation. Current therapies provide only symptomatic benefit and do not alter the disease course. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, are increasingly recognized as key modulators of PD pathogenesis, influencing oxidative stress, mitochondrial dysfunction, neuroinflammation, and proteostasis. Therapeutic modulation of miRNAs in PD has centered on two complementary approaches: miRNA inhibitors (antagomiRs), which silence pathogenic miRNAs, and miRNA mimics (agomiRs), which restore the activity of protective ones. This review integrates current insights into miRNA dysregulation in PD and evaluates the hurdles limiting therapeutic translation. Specific miRNAs such as miR‐7, miR‐153, and miR‐34b/c directly regulate SNCA expression, whereas others influence clearance pathways and stress responses. Although miRNA‐based therapeutics offer considerable promise, their clinical utility remains constrained by challenges of delivery, specificity, and standardization. This review highlights strategies to harness miRNA modulation as a targeted therapeutic avenue in PD.
- 22 April 2025
- Published by Wiley in Chemnanomat
- Vol. 11 (6)
Emerging Versatile Role of Carbon Quantum Dots in Theranostics Applications for Breast Cancer Management
Breast cancer (BC) is major malignancy condition among women globally. Despite significant advancements for its treatment, oncologists still encountering major challenges for the early diagnosis and prognosis due to lack of targeted therapies, which ultimately underscores the need for novel therapeutic approaches. In recent years, nanomaterials have emerged as promising tools for early diagnosis and treatment at the cellular level. Among these, carbon quantum dots (CQDs), a type of fluorescent carbon‐based nanoparticle have gained attention as versatile theranostics platforms in the biomedical fields. This review primarily focuses on the diverse roles of CQDs in BC, emphasizing their potential in targeted drug delivery, enhanced imaging, and combined therapeutic strategies. We explore the future of BC treatments by optimizing CQDs‐based nanomaterials and integrating them into drug delivery, active tumor targeting, photothermal therapy (PTT), photodynamic therapy (PDT), and bioimaging and biosensing applications. Furthermore, we highlight the recent advancements in the synthesis and biofunctionalization of CQDs. Our goal is to provide a comprehensive overview of CQDs as theranostics nanoparticle systems, aimed at enhancing both cancer diagnosis and therapeutic efficacy. This review also offers the scientific community an updated perspective on designing and expanding the advanced theranostics applications of CQDs in the treatment of BC.
- 22 April 2025
- Published by Wiley in Chemnanomat
- Vol. 11 (6)
Emerging Versatile Role of Carbon Quantum Dots in Theranostics Applications for Breast Cancer Management
Breast cancer (BC) is major malignancy condition among women globally. Despite significant advancements for its treatment, oncologists still encountering major challenges for the early diagnosis and prognosis due to lack of targeted therapies, which ultimately underscores the need for novel therapeutic approaches. In recent years, nanomaterials have emerged as promising tools for early diagnosis and treatment at the cellular level. Among these, carbon quantum dots (CQDs), a type of fluorescent carbon‐based nanoparticle have gained attention as versatile theranostics platforms in the biomedical fields. This review primarily focuses on the diverse roles of CQDs in BC, emphasizing their potential in targeted drug delivery, enhanced imaging, and combined therapeutic strategies. We explore the future of BC treatments by optimizing CQDs‐based nanomaterials and integrating them into drug delivery, active tumor targeting, photothermal therapy (PTT), photodynamic therapy (PDT), and bioimaging and biosensing applications. Furthermore, we highlight the recent advancements in the synthesis and biofunctionalization of CQDs. Our goal is to provide a comprehensive overview of CQDs as theranostics nanoparticle systems, aimed at enhancing both cancer diagnosis and therapeutic efficacy. This review also offers the scientific community an updated perspective on designing and expanding the advanced theranostics applications of CQDs in the treatment of BC.
- 16 April 2025
- Published by Taylor & Francis in Composite Interfaces
- Vol. 32 (11) , 1557-1613
Exploring the emerging technological expansions of MXenes-based nanomaterials: a comprehensive review
- 16 April 2025
- Published by Taylor & Francis in Composite Interfaces
- Vol. 32 (11) , 1557-1613
Exploring the emerging technological expansions of MXenes-based nanomaterials: a comprehensive review
- Open Access
Bioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies
Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, as abnormal membrane potentials and ion channel activity can drive tumor progression. In breast cancer, ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial–mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Neuroreceptors also play a key role, with dopamine receptor D2 activation reducing breast tumor growth by 40% in preclinical models, while serotonin signaling has been shown to promote epithelial–mesenchymal transition (EMT), increasing invasiveness. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Examining the modulation of bioelectricity through neuroreceptor pharmacology to influence breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.
Open AccessBioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies
Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, as abnormal membrane potentials and ion channel activity can drive tumor progression. In breast cancer, ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial–mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Neuroreceptors also play a key role, with dopamine receptor D2 activation reducing breast tumor growth by 40% in preclinical models, while serotonin signaling has been shown to promote epithelial–mesenchymal transition (EMT), increasing invasiveness. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Examining the modulation of bioelectricity through neuroreceptor pharmacology to influence breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.
- Open Access
- 29 January 2025
- Published by MDPI AG in Preprints.org
Bioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies
Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, particularly in breast cancer, where ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial-mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Investigating how neuroreceptor pharmacology-based modulation of bioelectricity affects breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.
- 29 January 2025
- Published by MDPI AG in Preprints.org
Open AccessBioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies
Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, particularly in breast cancer, where ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial-mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Investigating how neuroreceptor pharmacology-based modulation of bioelectricity affects breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.